Virax Biolabs Group Limit... (VRAX)
undefined
undefined%
At close: undefined
2.39
-2.05%
After-hours Jan 03, 2025, 05:56 PM EST

Company Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.

The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products.

It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines.

In addition, the company operates an online platform that sells ViraxClear and ViraxCare products.

It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions.

The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.

The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.

Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Limited
Virax Biolabs Group Limited logo
Country GB
IPO Date Jul 21, 2022
Industry Biotechnology
Sector Healthcare
Employees 17
CEO James Foster

Contact Details

Address:
30 Broadwick Street
London,
GB
Website https://viraxbiolabs.com

Stock Details

Ticker Symbol VRAX
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001885827
CUSIP Number G9495L109
ISIN Number KYG9495L1251
Employer ID 00-0000000
SIC Code 2835

Key Executives

Name Position
James Foster Chairman & Chief Executive Officer
Dr. Nigel McCracken M.Sc., Ph.D. Chief Operating Officer & Chief Technical Officer
Jason D. Davis Chief Financial Officer
Clement Monteil Head of Scientific Research & Development
Joel Yeung Accounting Manager
Lily Fu Head of Supply Chain

Latest SEC Filings

Date Type Title
Dec 23, 2024 6-K Filing
Dec 17, 2024 6-K Filing
Dec 10, 2024 6-K Filing
Nov 20, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 31, 2024 6-K Filing
Oct 23, 2024 6-K Filing
Sep 30, 2024 6-K Filing
Sep 30, 2024 424B5 Filing
Aug 23, 2024 6-K Filing